Market structure, R&D and advertising in the pharmaceutical industry

Journal of Industrial Economics

Volumn 47, Issue 2, 1999, Pages 169-194

  Matraves, Catherine ^a,b  

^a WZB BERLIN SOCIAL SCIENCE CENTER   (Germany)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002708712     PISSN: 00221821     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-6451.00096     Document Type: Article

References (44)

1. Ballance, R., Pogany, J. and Forstner, H., 1992, The World's Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy, Edward Elgar, Cheltenham.
2. Bogner, W., Thomas, H. and McGee, J., 1996, 'A Longitudinal Study of the Competitive Position and Entry Paths of European Firms in the US Pharmaceutical Market', Strategic Management Journal, 17, 2, pp. 85-107.
3. Bond, R. and Lean, D., 1977, 'Sales, Promotion and Product Differentiation in the Prescription Drug Markets', in Staff Report to the FTC, Washington DC: US Government.
4. Bresnahan, T., 1981, 'Departures from Marginal-Cost Pricing in the American Automobile Industry: Estimates for 1971-1978', Journal of Econometrics, 11, pp. 201-227.
5. Burstall, M. L. and Senior, I., 1992, Undermining Innovation: Parallel Trade in Prescription Medicines, IEA Health and Welfare Unit, London.
6. Casper, S. and Matraves, C., 1997, 'Corporate Governance and Firm Strategy in the Pharmaceutical Industry', WZB Discussion Paper FS IV 97-20.
7. Caves, R., Whinston, M. and Hurwitz, M., 1991, 'Patent Expiration, Entry, and Competition in the US Pharmaceutical Industry', Brookings Papers on Economic Activity, 1, pp. 1-48.
8. Cool, K., Röller, L.-H. and Leleux, B., 1998, 'The Relative Impact of Actual and Potential Rivalry on Firm Profitability in the Pharmaceutical Industry', forthcoming in Strategic Management Journal.
9. Danzon, P., 1996, 'The Uses and Abuses of International Price Comparisons', in Competitive Strategies in the Pharmaceutical Industry, Helms, R. (ed.), American Enterprise Institute for Public Policy Research, Washington.
10. Davies, S. W. and Rondi, L., 1996, 'Intra-EU Multinationality of Industries', in Davies, S. W. and Lyons, B. R. et al., Industrial Organisation in the European Union: Structure, Strategy and the Competitive Mechanism, Oxford University Press, Oxford.
11. Di Masi, J., Hansen, R., Grabowski, H. and Lasagna, L., 1991, 'Cost of Innovation in the Pharmaceutical Industry', Journal of Health Economics, 10, pp. 107-142.
12. Dranove, D., 1991, 'The Costs of Compliance with the 1962 FDA Amendments', Journal of Health Economics, 10, pp. 235-238.
13. Earl-Slater, A., 1993, 'Pharmaceuticals', in European Industries: Structure, Conduct and Performance, Johnson, P. (ed.), Edward Elgar, Cheltenham.
14. European Economy, 1996, Economic Evaluation of the Internal Market, European Commission.
15. Grabowski, H. and Vernon, J., 1990, 'A New Look at the Returns and Risks to Pharmaceutical R&D', Management Science, 36, pp. 804-821.
16. Grabowski, H. and Vernon, J., 1992, 'Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act', Journal of Law and Economics, 35, pp. 331-350.
17. Grabowski, H. and Vernon, J., 1994a, 'Innovation and Structural Change in Pharmaceuticals and Biotechnology', Industrial and Corporate Change, 3, pp. 435-449.
18. Grabowski, H. and Vernon, J., 1994b, 'Returns to R&D on New Drug Introductions in the 1980s', Journal of Health Economics, 13, pp. 383-406.
19. Hansen, R., 1979, 'The pharmaceutical development process: estimates of current development costs and times and the effects of proposed regulatory changes', in Chien, R. I. (ed.), Issues in Pharmaceutical Economics, Lexington Books, Lexington, MA.
20. Henderson, R. and Cockburn, I., 1996a, 'Scale, Scope and Spillovers: the Determinants of Research Productivity in Drug Discovery', Rand Journal of Economics, 27, pp. 32-59.
21. Henderson, R. and Cockburn, I., 1996b, 'The Determinants of Research Productivity in Ethical Drug Discovery', in Competitive Strategies in the Pharmaceutical Industry, Helms, R. (ed.), American Enterprise Institute for Public Policy Research, Washington.
22. Hendricks, K., Porter, R. A. and Boudreau, B., 1987, 'Information, Returns and Bidding Behaviour in OCS Auctions: 1954-1969', Journal of Industrial Economics, 35, pp. 517-542.
23. Klepper, G., 1992, 'Pharmaceuticals: Who's Afraid of 1992?', in Winters, Alan, L. (ed.), Trade Flows and Trade Policy after 1992, Cambridge University Press, Cambridge.
24. Lyons, B. R. and Matraves, C., 1996, 'Industrial Concentration', in Davies, S. W. and Lyons, B. R. et al., Industrial Organisation in the European Union: Structure, Strategy and the Competitive Mechanism, Oxford University Press, Oxford.
25. Lyons, B. R., Matraves, C. and Moffatt, P., 1998, 'Industrial Concentration and Market Integration in the European Union', Working Paper, WZB.
26. Panorama of EC Industry, 1995, Commission of the European Communities, Brussels.
27. Penan, H., 1996, 'R&D Strategy in a Techno-Economic Network: Alzheimer's Disease Therapeutic Strategies', Research Policy, 25, pp. 337-358.
28. PhRMA Industry Profile, 1996 and 1997 issues, Washington DC.
29. Pisano, G. and Wheelwright, S., 1995, 'The New Logic of High-Tech R&D', Harvard Business Review, pp. 93-105.
30. Robinson, W. T. and Chiang, J., 1996, 'Are Sutton's Predictions Robust? Empirical Insights into Advertising, R&D and Concentration', Journal of Industrial Economics, pp. 389-408.
31. Schmalensee, R., 1992, 'Sunk Costs and Market Structure: A Review Article', Journal of Industrial Economics, pp. 125-134.
32. Schwartzman, D., 1976, Innovation in the Pharmaceutical Industry, Johns Hopkins University Press, Baltimore.
33. Scrip Yearbook, 1995, Scrip Reports, PJB Publications Ltd.
34. Senker, J., Joly, P.-B. and Reinhard, M., 1996, 'Overseas Biotechnology Research by Europe's Chemical/Pharmaceuticals Multinationals: Rationale and Implications', Final report for EC Biotech Project, SPRU, University of Sussex.
35. Shapiro, C., 1989, 'The Theory of Business Strategy', Rand Journal of Economics, pp. 125-137.
36. Sharp, M. and Patel, P., 1996, 'Europe's Pharmaceutical Industry: An Innovation Profile', Draft Report Prepared for DG X111, European Commission.
37. Slade, M., 1987, 'Interfirm Rivalry in a Repeated Game: An Empirical Test of Tacit Collusion', Journal of Industrial Economics, 35, pp. 499-516.
38. Sutton, J., 1991, Sunk Costs & Market Structure: Price Competition, Advertising, and the Evolution of Concentration, MIT Press, London.
39. Sutton, J., 1996, 'Technology and Market Structure', European Economic Review, pp. 511-530.
40. Sutton, J., 1998, Technology and Market Structure: Theory and History, forthcoming, MIT Press.
41. Symeonidis, G., 1997a, 'Price Competition and Market Structure: the Impact of Restrictive Practices Legislation on Concentration in the UK', LSE Sticerd EI/18.
42. Symeonidis, G. 1997b, 'Cartel Policy, Non-Price Competition and Market Structure: Theory and Evidence from the UK', LSE Sticerd, EI/19.
43. Temin, P., 1979, 'Technology, Regulation and Market Structure in the Modern Pharmaceutical Industry', Bell Journal of Economics, 10, pp. 429-446.
44. Thomas, L. G., 1996, 'Industrial Policy and International Competitiveness in the Pharmaceutical Industry', in Competitive Strategies in the Pharmaceutical Industry, Helms, R. (ed.), American Enterprise Institute for Public Policy Research, Washington.